Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies

Fig. 2

Cumulative survival without events during 1-year of follow-up (based on Cox regression analysis), in (a) the whole population of patients treated (+) or not treated (-) with Xantine-oxidase inhibitors, (b) patients receiving zofenopril with xanthine oxidase inhibitors (+) as respect to those treated with zofenopril alone (-), (c) those treated with zofenopril (zofenopril+) vs. placebo or other angiotensin converting enzyme (ACE)-inhibitors both in combination with and xanthine-oxidase inhibitors (ACE-inhibitors+) and (d) those treated with zofenopril and xanthine-oxidase inhibitors (zofenopril+) vs. placebo or other ACE-inhibitors without XOIs (ACE-inhibitors-). P-values for the between-group comparison are reported in each panel

Back to article page